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Conditioned stimulus (CS): generally a motivationally neutral stimulus such as
light or auditory tone that gains salience by being predictive of an
unconditioned stimulus or reinforcer such as food or electric shock.
Consolidation: the memory process by which short-term memory represen-
tations (or ‘traces’) are made more permanent, leading to memory storage.
Declarative memory: generally used to denote conscious recollection of
autobiographical events (‘episodic memory’) or facts (e.g. routes or capitals of
countries: ‘semantic memory’.
Discriminated approach: a form of conditioning in which the animal is trained
to approach one stimulus rather than another stimulus.Behavioural pharmacology is an interdisciplinary field at
the intersection of several research areas that ultimately
lead to the development of drugs for clinical use and
build understanding of how brain functions enable
cognition and behaviour. In this article, the development
of behavioural pharmacology in the UK is briefly
surveyed, and the current status and success of the
field is highlighted by the progress in our understanding
of learning and memory that has resulted from dis-
coveries in glutamate receptor pharmacology allied to
theoretical and methodological advances in behavioural
neuroscience. We describe the original breakthrough in
terms of the role of NMDA receptors in hippocampal-
mediated spatial learning and long-term potentiation,
and review recent advances that demonstrate the
involvement of glutamate receptor in working memory,
recognition memory, stimulus–response learning and
memory, and higher cognitive functions. We also
discuss the unique functions of NMDA receptors and
the fundamental role of AMPA receptors in processes
that are common to some of these forms of memory,
including encoding, consolidation and retrieval.Extinction: when the reinforcer (e.g. food or shock) associated with learning a
particular task or response is omitted or withdrawn.
Instrumental learning: a form of learning in which a voluntary action produces
an outcome or goal (e.g. leading to a reward or the postponement of an
aversive stimulus; both of these are termed reinforcers, hence the term
reinforcement learning. This type of learning contrasts with Pavlovian
(classical) conditioning.
Learned contextual fear: a form of Pavlovian conditioning in which fear is
conditioned to an entire environment or setting rather than a discrete CS.
One trial ‘place memory’ test: a specialised test of spatial memory in which a
specific location is associated with reinforcement (e.g. food or safety) in one
trial only.
Recognition memory: a simple form of declarative memory in which, for
example, a visual object such as a face becomes familiar.
Retrieval: the memory process by which memories are summoned from long-
term storage, and converted from a ‘passive’ to an ‘active’ form.
Stimulus–response habits: generally highly over-trained instrumental learning
that is less dependent on the outcome or goal and is performed somewhat
automatically, compared with normal levels of training.
Unconditioned stimulus (US): generally a reinforcer such as food or shock that
elicits unconditioned responses (such as salivation to food) and is subject to
Pavlovian conditioning following several pairings with a predictive CS.
Wisconsin card sorting task: a cognitive test in which the ability to deduce rules
and shift rules on the basis of trial-and-error learning is required. It is often used
clinically as a test of cognitive flexibility; patients with frontal lobe damage or
dysfunction often fail by perseverating with the original rule.
Working memory: not simply short-term memory, but memory that involves
the manipulation (or ‘encoding’) of sensory representations into more-
persistent representations during short periods of time. It is often equatedBehavioural pharmacology and its origins
Behavioural pharmacology (or psychopharmacology) is at
a practical interface between the discovery of a novel
pharmacological agent that acts on the CNS and the
assessment of its utility, whether clinically as a thera-
peutic agent or for analytical purposes in psychology and
neuroscience. Consequently, it is important to use precise
methods for assessing and interpreting the effects of drugs
on behaviour in humans and experimental animals.
Adequate preclinical screening of drugs by pharmaceu-
tical companies is essential for selecting candidates for
expensive Phase II and III clinical trials. Furthermore,
appropriately measuring behaviour is vital to test
speculative hypotheses about the consequences of neur-
onal plasticity based on the effects of drugs observed in
cultured tissue slices or the consequences of genetic
manipulations for a particular neurotransmitter receptor.
Behavioural pharmacology must thus be an integralCorresponding author: Robbins, T.W. (twr2@cam.ac.uk).
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In this article, we review briefly the origins of behavioural
pharmacology in the UK and as a particular example of its
success show how it has been instrumental in under-
standing more precisely the role of glutamate as a
neurotransmitter in the processes of neuronal plasticity,
with particular reference to learning and memory.
Behavioural pharmacology has flourished in the UK
and worldwide, although it has evolved in several
directions from different intellectual precursors andReview TRENDS in Pharmacological Sciences Vol.27 No.3 March 2006with the ‘online’ maintenance of representations in the solution of a problem or
the retrieval of memory.
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cology, psychiatry, neuroscience, ethology and several
different traditions in psychology, each driven by a set of
goals unique to the discipline. One of the main origins of
behavioural pharmacology in the UK is work carried out
in the Department of Pharmacology at University College
London in the 1950s and 1960s. During this time, Roger
Russell, the then Head of Department, encouraged
Hannah Steinberg, in collaboration with Ian Stolerman
and the late R. ‘Channi’ Kumar, to base their research
programme on the behavioural effects of mixtures of
stimulants and barbiturates in addition to opiates in
experimental animals. Another major, but different,
approach came from the field of psychiatry, where figures
such as Max Hamilton and Alex Coppen had an interest in
the treatment and aetiology of depression and other forms
of mental illness. Hamilton constructed influential clinical
scales for assessing both depression and anxiety in
humans that are used today in evaluating the therapeutic
efficacy of novel pharmacological agents. Both of these
influences differed markedly from the development of
behavioural pharmacology in the USA, which arose from a
fusion of classic pharmacology and Skinnerian ‘operant’
psychology, as exemplified by the Harvard Medical School
laboratory founded by Peter Dews, Roger Kelleher and
Bill Morse. Although Harvard Medical School exerted an
enormous influence over the methods used in the UK, in
the late 1960s and early 1970s the late Jeffrey Gray at
Oxford University and Susan Iversen at Cambridge
University introduced two novel approaches to enrich
behavioural pharmacology, the former depending on
animal learning theory [1], and the latter depending on
a fusion between neuropsychology, neurochemistry and
traditional behavioural pharmacology [2]. Both
approaches focused on the study of how drugs worked on
defined neural systems, using powerful behavioural
paradigms; these advances continue to influence the
work of current researchers. Iversen’s move to the
Merck, Sharp and DohmeNeuroscience Centre at Terlings
Park, Harlow, UK is just one example of how academic
scientists moving to the pharmaceutical sector enabled
the application of evolving psychopharmacological meth-
odology to the evaluation of new compounds.
A landmark international CIBA symposium, ‘Animal
Behaviour and Drug Action,’ held in London in 1963 and
published a year later [3], contained several contributions
from British psychopharmacology that reflected some of
these origins. Reviewing the various contributions now, it
is notable how contemporarymany of the themes discussed
at the meeting remain today. There were several chapters
on the influence of drugs on memory (Jarvik) and learning
(Bures and Russell), in addition to other current foci of
research interest such as pharmacological interactions
with frontal lobe functioning (Weiskrantz), amphetamine
and neural reward mechanisms (Stein), and pharmacoge-
netics (Broadhurst). Furthermore, an entire section of the
meeting was devoted to the relevance of the behavioural
effects of drugs in animals and humans, thus presaging the
current emphasis on translational neuroscience.
What has changed since then? Many of the funda-
mental conceptual questions have remained the same,www.sciencedirect.comalthough they have become much more refined as a result
of major advances in theory and methodology in exper-
imental psychology and major discoveries (e.g. new
neurotransmitter systems and multiplicities of novel
receptor mechanisms) in neuropharmacology. Although
learning and memory were important topics in the CIBA
symposium and behavioural pharmacologists had begun
to work out how best to study these functions, a possible
role for glutamate in learning and memory was largely
unsuspected. However, Jeffrey Watkins and colleagues
(Bristol, UK) were, at that time, investigating the possible
role of glutamate as a neurotransmitter [4], which had
been a controversial issue since Hayashi’s initial obser-
vations [5] that central infusions of glutamate produced
convulsions in experimental animals. In a recent review,
Watkins [6] charts the stages by which glutamate
gradually passed the stringent criteria for being a
neurotransmitter substance, including structural and
stereochemical specificity for actions at defined receptors,
presynaptic release during axonal activity, the presence of
an inactivation mechanism and the effect of specific
antagonists on the production of excitatory postsynaptic
potentials (EPSPs) by glutamate and the excitatory
potential of the presumed neurotransmitter. Arguably
the most impressive of all indications suggesting that
glutamate is a neurotransmitter, however, came from
behavioural pharmacology studies that demonstrated an
intimate association between glutamate receptors and
neuronal plasticity and complex behavioural functions,
including learning and memory. These studies are
reviewed here.
The anti-epileptic agent MK801 (dizocilpine), with a
hitherto unknown mechanism of action, was first dis-
covered to be a non-competitive antagonist at NMDA
receptors by the UK Merck group at Terlings Park [7] and
was one of the many tools that became available from
pharmaceutical companies in the 1980s for the study of
the role of glutamate receptors in learning. This topic has
thus been a prime example of the crucial and sustained
contributions of academic and industrial behavioural
pharmacologists and neuroscientists in the UK in what
is now an increasingly collaborative, international enter-
prise. In the search for new drugs, this research field is
now being linked to the modelling of hitherto pathologi-
cally elusive clinical disorders, including Alzheimer’s
disease and schizophrenia, in addition to less-obvious
examples such as general anxiety disorder and
drug addiction.
The behavioural pharmacology of learning and memory:
focus on glutamate receptors
Initial breakthrough
A key breakthrough in understanding the neural basis of
learning has been the realization that there are different
types of memory subserved by different neural systems.
Thus, there is a declarative form of long-term memory for
episodes and facts that appears to be mediated mainly by
structures of the medial temporal lobe. Other forms of
memory, such as perceptuo-motor skills and some forms of
Pavlovian and instrumental learning (including stimu-
lus–response habits) (see Glossary) appear to devolve to
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ventral striatum, and cerebellum [8]. By contrast,
information that is used for only a short time and has to
be kept ‘online’ for that purpose requires ‘working
memory’ processes that implicate the prefrontal cortex,
certain areas of the posterior cortex and the hippocampus
[9]. However, although these dissociable forms of memory
imply different forms of information processing in
different brain regions, they might nevertheless be
mediated by similar cellular and molecular mechanisms.
Thus, it is increasingly appreciated that neuronal
plasticity processes represented by cellular phenomena
such as long-term potentiation (LTP) [and also long-term
depression (LTD)] might underlie different forms of
learning and memory. The neuropharmacology of LTP
itself is complex and beyond the scope of this article but it
is known to depend crucially on glutamate-mediated
transmission. Classically, blockade of the NMDA subtype
of glutamate receptors blocks LTP in slice preparations, as
originally observed by the British neuropharmacologist
Graham Collingridge while working with Hugh McLen-
nan and colleagues [10,11] However, the salient obser-
vation for behavioural pharmacology, discovered by
Richard Morris and colleagues at Edinburgh, was that
blockade of NMDA receptors also inhibited certain forms
of learning, at comparable doses of the NMDA receptor
antagonist to those that inhibited LTP. Thus, Morris and
colleagues [12] showed that intracerebroventricular infu-
sion of D-2-amino-5-phosphonopentanoic acid (AP-5), a
competitive NMDA receptor antagonist, selectively
impaired spatial learning in a water-maze escape task
known to depend on the integrity of the hippocampus, but
did not affect visual learning in the same maze. The
remarkable observation was that this treatment did not
have any effects on already established performance,
indicating the effects were not obviously dependent on
ancillary processes such as motivation, sensory perception
or motor function. This selectivity of effect on task
acquisition implies a direct action on associative
learning mechanisms.
The generality of the involvement of NMDA receptors
in learning
The basic findings of the seminal study by Collingridge
and McLennan have been substantiated by many sub-
sequent demonstrations of impaired learning following
manipulation of hippocampal NMDA receptors, whether
by pharmacological experiments (generally employing
rats) or genetic means (using mice). For example, Young
and colleagues [13] showed that NMDA receptor blockade
in the hippocampus impaired the normal learning of
associations between an environmental setting or context
and an electric shock (‘contextual fear’). Although it was
initially thought that there might be a special relationship
between NMDA receptors and spatial or contextual
learning that is dependent on the hippocampus, other
studies quickly showed that the effects of NMDA receptor
blockade on learning were more general and implicated
both other neural structures and other behavioural
assays. For example, deficits in the acquisition of both
fear conditioning and appetitive conditioning to discretewww.sciencedirect.comstimuli in rats (i.e. approach to food-predictive cues) were
shown to depend on NMDA receptors within the amygdala
[14,15]. A form of stimulus–response learning that is
dependent on the dorsal striatum (approaching cues that
are predictive of reward) has also been shown to depend on
NMDA receptors [16], and Dalley and colleagues [17]
recently showed that the consolidation of appetitive
approach behaviour to a conditioned stimulus predictive
of food delivery was similarly dependent on NMDA (in
addition to dopamine D1) receptors in the ventral
striatum. Furthermore, DiCiano and colleagues [18]
showed that NMDA receptor antagonism in the core of
the nucleus accumbens impaired acquisition of approach
behaviour, whereas AMPA receptor antagonism impaired
performance by disrupting discriminated approach. This
growing catalogue of learning and memory deficits
following NMDA receptor blockade has prompted several
questions: what precise aspects of learning and memory
are impaired, what is the role of other glutamate receptors
(such as the AMPA subtype, which mediates fast
depolarization by glutamate neurons, a prerequisite to
NMDA receptor activation), and what therapeutic signifi-
cance do these findings hold? For example, would it be
feasible to enhance rather than impair learning or
memory by manipulating glutamate-mediated trans-
mission? New discoveries in behavioural pharmacology,
enabled by the development of highly specific glutamater-
gic agents [19], are beginning to answer these questions.
Pharmacological dissection of encoding, consolidation
and retrieval memory processes
The issue of which component of memory might be
impaired concerns the processes implicated in initial
encoding, later consolidation and storage, and the
subsequent retrieval of the memory trace. These factors
can be interrogated using so-called ‘one-trial’ memory
tasks where (Figure 1) the agent of interest can be
administered either before or just after initial learning
and its effects on memory retrieval assessed by a
subsequent retention test, possibly several days or more
later. An agent that is only effective for a limited time-
interval after training is said to affect consolidation rather
than initial encoding of the trace. The agent can also be
administered just before retention to test possible effects
on memory retrieval (in addition to so-called ‘state-
dependent’ effects, where the state change produced by
the drug potentially acts as a memory-retrieval cue).
Thus, the effects of blockade of NMDA receptors and other
subtypes of glutamate receptors on different stages of
memory can be determined. In one-trial ‘place memory’
tests, NMDA receptor blockade disrupted encoding and
consolidation of the memory, but not retrieval [20]. Some
of these effects were delay dependent, in the sense that
they varied with the delay to the retention test, with
greater deficits at long retention intervals [21]. A similar
pattern of findings has been found for learned fear of
contexts [22]. This implies that NMDA receptors have a
selective role in the processes by which initially encoded
events are made more permanent in long-term memory.
By contrast, blockade of AMPA and kainate receptors
with a selective antagonist such as LY326325 (see
Home-cage context (e.g. 1–7 days)
Attention, encoding,
(working memory)
Learning Memory
Consolidation Retrieval
(working memory)
(a)
Acquisition
trial (5 min)
Retention
test (5 min)
(b)
Pre-trial
treatment
Post-trial treatments Pre-trial
treatment
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Figure 1. Stages of memory processing inferred from the results of neuropharmacological experiments. Depicted are two trials of any standard learning paradigm: (a)
acquisition training and (b) retention testing. Pharmacological interventions before acquisition can potentially affect a range of sensory, perceptual, attentional, motivational
and motor performance factors, in addition to learning and memory processes. To rule out the nonspecific factors that affect learning and memory per se, it is usually
necessary to compare the effects on performance that is previously established (e.g. after a single trial of training as in the retention test). A lack of effect on retention indicates
a specific effect on learning or memory-related processes such as encoding or memory consolidation. A lack of effect on initial training in acquisition accompanied by an
effect on retention usually indicates a specific effect on memory consolidation or retrieval. The post-trial manipulations administered after the acquisition trial (e.g. in the
home cage) cannot affect simple performance factors during the acquistion trial but do affect the hypothetical processes of memory consolidation. The time-limited nature of
consolidation means that post-trial treatments soon after the first trial will affect memory consolidation, indicated by performance in the retention test, typically 1–7 days
later. However, ineffective post-trial treatments at later time-points than immediate post-trial indicate the temporally limited nature of the consolidation process and rule out
proactive effects of post-trial treatments themselves on the retention test. Working memory is an active process of memory that is usually engaged soon after perceptual
processing to encode memory traces into passive storage. However, memories that are re-activated by memory cues also place retrieval memory traces into an active form in
working memory for the guidance of behaviour (see [8,28] for further details).
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consolidation and retrieval of spatial memories, showing
that fast synaptic transmission via AMPA receptors is
required more generally for all of these processes [23].
This selectivity of the role of NMDA compared with AMPA
receptors has subsequently been demonstrated for some
other forms of memory mediated by the hippocampus,
such as event-place associations in the rat, which are more
readily linked to the forms of episodic memory deficits that
are shown by patients with Alzheimer’s disease. In this
example, rats were trained to associate flavours with
particular places where they had found those flavours in
single episodes (or trials). Again, blockade of NMDA
receptors within the hippocampus impaired encoding but
not retrieval of the flavour–place associations, whereas
blockade of AMPA receptors using CNQX (6-cyano-7-
nitroquinoxaline-2,3-dione) disrupted encoding and
retrieval [24]. Parallel studies using an ingenious test of
memory consolidation based on non-spatial, socially
transmitted food preferences also shows that NMDA
receptors are not simply implicated in spatial encoding,
but are also implicated in non-spatial aspects of ‘declara-
tive’ learning [25].
Recognition memory and working memory
Most recently, the involvement of NMDA and AMPA
receptors has been demonstrated in another aspect of
memory – the ability to recognize objects, which isChemical names
HA966: (C)-3-amino-1-hydroxypyrrolid-2-one
LY326325: (3RS,4aRS,6RS,8aRS)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]-
decahydro-isoquinoline-3-carboxylic acid
www.sciencedirect.commarkedly impaired in Alzheimer’s disease. There is now
strong evidence that object recognition is more dependent
on a specific region of the medial temporal lobe, the
perirhinal cortex, than on the hippocampus [26,27].
Recently, Winters and Bussey [28] have capitalized on
this functional localization by administration of infusions
of selective NMDA and AMPA receptor antagonists into
the perirhinal cortex in rats at varying stages of
performance of a visual object-recognition task. In this
test, rats are allowed to interact with and explore a novel
object before experiencing that now-familiar object again
at a later time in conjunction with another object.
Recognition memory can be inferred by the relative
proportion of time the rats spend exploring the familiar
and novel objects during a retention test carried out either
a short or a longer time following the original presentation
of the first object. The authors found that NMDA receptor
blockade (using AP-5) impaired long- but not short-term
object-recognition memory when infused before encoding
the initial object (Figure 2a). This result suggests that
NMDA receptors within the perirhinal cortex are not
necessary for the initial perceptual encoding of the object
but are required for the induction of synaptic plasticity
required for the long-term storage of its trace. Moreover,
NMDA receptor blockade soon after experience of the
initial object also inhibited its subsequent recognition,
showing that NMDA receptors are directly implicated in
memory consolidation (Figure 2b). By contrast, NMDA
receptor blockade immediately before the retention test
had no effects on recognition memory, whereas AMPA
receptor blockade (via CNQX) did disrupt retrieval, which
parallels the findings for spatial memory in the hippo-
campus. AMPA receptor blockade also deleteriously
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Figure 2. Results from a study on the effects of drugs on glutamate receptors following infusion of the drugs into the rat perirhinal cortex [28]. The study by Winters and
Bussey [28] examined, for the first time, the effects of glutamate receptor manipulations on visual-recognition memory (memory for a familiar object) in experimental
animals, following administration of the drugs at pre-acquisition, post-training trial or pre-retention test stages. This enabled identification of the nature of the involvement of
glutamate receptors in the different phases of memory according to the logic described in Figure 1. Substances were infused directly into the rat perirhinal cortex via
implanted cannulae because this region has been implicated in visual-recognition memory processes (see main text for further details). (a) NMDA receptor blockade in the
perirhinal cortex following administration of AP5 impairs long-term but not short-term object recognition memory. (b)AMPA receptor blockade and NMDA receptor blockade
in the perirhinal cortex following CNQX and AP5 administration, respectively, disrupts consolidation of object-recognition memory for up to 40 min post-trial. (c) AMPA
receptor blockade but not NMDA receptor blockade in the perirhinal cortex disrupts retrieval in object-recognition memory during the retention test.q2005 by the Society for
Neuroscience [28].
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tion and retrieval (Figure 2c). Thus, it appears that there
is considerable generality in the glutamate mechanisms
that mediate memory across not only domains (i.e. the
nature of the memories), but also common memory
processes, such as consolidation (Table 1).
Another way of defining the roles of glutamate receptor
subtype function in memory is to employ mutant mice
with targeted genetic deletions. Thus, evidence from mice
that lack the AMPA receptor subunit A (GluRA/GluR1)
supports the role of fast synaptic transmission in working
memory functions, as measured in a delayed alternation
paradigm where the mice simply have to remember which
arm they last visited in a T maze [29]. The striking aspect
of these data was that these mice were relatively
unimpaired in a spatial task requiring longer-term
memory and NMDA receptor involvement in the hippo-
campus, suggesting that different neuronal mechanismsTable 1. Involvement of NMDA and AMPA receptors in cognitive fu
Visual recognition
Declarative memory NMDA (K) AMPA (K
Encoding K Y
Consolidation Y Y
Retrieval K Y
Appetitive and aversive cond
Associative conditioning NMDA (K) AMPA (K
Acquisition (encoding/consolidation) Y K
Performance (retrieval) K Yc
Executive functions NMDA (K) AMPA (K
Working memory Y Yd
Discrimination learning Y Xe
aSymbols: (K), pharmacological antagonism; (C), direct or indirect agonism; (KO), gene
not affected.
bSome effects are mediated in specific brain areas; see main text for details.
cDiscriminated approach to appropriate stimulus disrupted; a generalized deficit.
dLow systemic doses impair performance only at long retention intervals.
eGeneralized cognitive disruption.
www.sciencedirect.comwithin the hippocampus contribute to different (although
probably interactive) types of information processing. One
possible explanation for these possibly paradoxical
results, given the normal close functional interdepen-
dence of NMDA and AMPA receptors, is that the targeted
subunit deletion does not impair the function of the entire
population of AMPA receptors such that NMDA receptor-
mediated synaptic plasticity could be activated by a
GluRA-independent mechanism. In previous studies,
NMDA receptors had been implicated in spatial working
memory functions in rodents, based on behavioural
pharmacological evidence [21,30].Cognitive enhancement via glutamate receptors?
The explosion in knowledge about the nature of the
glutamate receptors involved in learning and memory and
the regulation of glutamate-mediated transmission begs
the question of how such information might be used tonctionsa,b
Spatial learning
) NMDA (K) AMPA (K)
K Y
Y Y
K Y
itioning Extinction
) NMDA (K) NMDA (C) AMPA (K)
Y [ K
) AMPA (KO)
Y
tic knockout model; [, function is improved; Y, function is impaired;K, function is
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function [19]. The rather specific effects of NMDA receptor
agents on the processes that link encoding to consolidation
might encourage the further testing of this hypothesis
by postulating selective enhancements with agonists.
However, this strategy is weakened by the likelihood of
serious side-effects (e.g. epilepsy and neurotoxicity) as a
result of surplus activity of glutamate receptors. Some
grounds for optimism are provided by effects reported on
long-term memory recall in human volunteers by ‘AMPA-
kine’ drugs that enhance excitatory glutamate trans-
mission via their actions as positive allosteric modulators
of the AMPA receptor [31]. Additionally, interest has
focused on partial agonists that facilitate NMDA receptor
activity in amore indirect way. For example, D-cycloserine
(DCS) acts at the strychnine-insensitive glycine recog-
nition site of the NMDA receptor complex [6], and,
remarkably, has been shown to improve learning and
memory in several animal tests, including visual-recog-
nition memory in non-human primates [32] and maze
learning and associative learning in both rats and mice
[33,34]. Small beneficial effects have also been reported in
clinical studies of schizophrenia [35] and Alzheimer’s
disease [36], although in some cases these promising
results have proven difficult to replicate [37]. Notwith-
standing this controversy, recent animal work has
shown reproducible effects of DCS in experimental
animals on a special sort of learning process, extinction
learning, that is also dependent on NMDA receptors and
has considerable implications for the treatment of other
neuropsychiatric disorders.
The relatively recent discovery of another class of
glutamate receptors, the metabotropic subtypes, has
opened another strategic avenue in the modulation of
glutamate-mediated transmission. These G-protein-
coupled receptors (for reviews see [38,39]) modulate
neuronal activity (versus the fast excitatory or inhibitory
functions of ionotropic receptors such as AMPA and
NMDA types) and are heterogeneously distributed,
making them highly promising drug targets. Indeed,
recent work has focused on their potential for improving
cognitive deficits in schizophrenia [40], and applications
are being investigated across the full spectrum of
neurological and psychiatric disorders [41].
The behavioural pharmacology of extinction learning:
focus on glutamate receptors
Extinction occurs when the reinforcer (e.g. food or shock)
associated with learning a particular task is omitted or
withdrawn. Previously conditioned behaviour shows a
gradual decline of responding during extinction, which
suggested to early theorists that a form of ‘unlearning’ of
the association must be occurring. However, recent
findings have suggested that a new learning process
occurs during extinction that has the effect of suppressing
the conditioned stimulus–unconditioned stimulus
(CS–US) association, although the memory of the associ-
ation is preserved [42]. NMDA, but not AMPA, receptor
antagonists have been known for some time to block
extinction of learned fear, which means that an aversive
CS continues to elicit fear in the absence of the US [43,44].www.sciencedirect.comThis retardation of extinction also occurs following intra-
amygdaloid administration of AP-5 [44]. However, the
striking recent finding has been that DCS accelerates
extinction in the same learned-fear paradigm whether
administered systemically or infused into the amygdala
[45]. Several control experiments in this study showed
that these effects could not be attributed to actions on fear-
potentiated startle itself and that they were attenuated by
HA966, an antagonist at the strychnine-insensitive
glycine site [6].
Because current behavioural therapies for human
anxiety disorders are explicitly based on the process of
extinction (suppressing a learned association between a
stimulus and anxiety by ‘relearning’ a new association
that overrides the maladaptive state), the pharmacologi-
cal enhancement of this process holds considerable
promise for the treatment of these conditions. A recent
study has directly tested this idea by showing that orally
administered DCS produced a faster reduction of fear of
heights than placebo in patients with anxiety, using a
virtual-reality testing paradigm [46]. One of the problems
with extinction therapy is that the effects learned in one
situation fail to generalize to others, and thus its effects
might be too limited to be of any therapeutic value.
However, a recent study [47] has shown in rats that DCS
not only facilitates extinction to an extinguished CS, but
also reduces the fear of a second CS that does not undergo
extinction itself: that is, the rats exhibited generalized
fear extinction. Other forms of psychopathology such as
drug addiction, which might arise in part from maladap-
tive conditioning processes, might also be treatable with
this pharmacological strategy.
The behavioural pharmacology of higher cognitive
function: focus on glutamate receptors
The conceptualisation of extinction as a special form of
inhibitory conditioning, and its apparent dependence on
prefrontal cortical mechanisms [48], is consistent with the
hypothesis that glutamate receptors are implicated in
forms of plasticity that are important for the cognitive
control (often termed ‘executive’) functions of the pre-
frontal cortex. These cognitive functions, however, operate
rapidly over short time-scales and endow the animal with
the flexibility to respond to a changing environment. One
such function is working memory, which requires the
maintenance of information ‘online’ over short periods to
guide future behaviour while resisting distractions [9].
Working memory functions that are dependent on the
prefrontal cortex (PFC) are impaired by NMDA receptor
antagonists such as ketamine (a non-competitive NMDA
receptor antagonist) in humans [49]. A complementary
prefrontal capacity is the shifting of attention to different
aspects of otherwise ambiguous stimuli to reliably earn
predicted reward. Patients with frontal lobe damage or
schizophrenia are well known to be poor at making such
shifts in clinical tests such as the Wisconsin card sorting
task. This type of attentional shifting is also impaired
by ketamine in healthy human volunteers [50]. Recently,
it was shown that NMDA receptor blockade (using
the non-competitive antagonist MK801 infused into the
rat prefrontal cortex) impaired the capacity to shift
Review TRENDS in Pharmacological Sciences Vol.27 No.3 March 2006 147attentional set, causing animals to perseverate (maladap-
tively repeat) in responding to visual cues when the
rewards were instead predicted by the texture of the
floor [51]. AMPA receptor blockade within the PFC
impaired performance in a nonspecific way, affecting
not only shifting but also discrimination learning,
which is reminiscent of its generalized effects on
memory processes.
These exciting data indicate that some of the highest
levels of cognitive functioning, impaired in such complex
conditions as schizophrenia, are also susceptible to
NMDA receptor manipulation, and therefore impair-
ments might be remediated by glutamate receptor
agents. Whether such basic processes as LTP will be
shown to underlie such rapid flexibility in behavioural
control, or whether such effects depend on another
pharmacological action at NMDA receptors, is not yet
clear. However, results such as these suggest that a much
more sophisticated understanding of what is meant by
the term ‘neuronal plasticity’ is required. Almost 20 years
following the original implication of NMDA receptors in
spatial learning, the role of these receptors has expanded
to include many other forms of learning and memory.
Furthermore, distinct roles have emerged for unique
glutamate receptor subtypes, with further understanding
of more recently discovered subtypes on the horizon
(Table 1). These developments have strong potential
therapeutic implications, and it seems that the next
decade of collaborative enterprise between behavioural
pharmacology and neuroscience will probably uncover
some of these promising possibilities.Acknowledgements
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